Brief communication
Circulating tumor DNA (ctDNA) levels may predict response to anticancer drugs1, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET)2; however, critical questions remain unanswered such as which assay or statistical method to use3. Here, we obtained paired plasma samples at baseline and week 4 in 45 consecutive patients with advanced breast cancer treated with CDK4/6i+ET. ctDNA was detected in 96% of cases using the 74-gene Guardant360 assay4,5. A variant allele fraction ratio (VAFR) was calculated for each of the 79 detected mutations between both time-points. Mean of all VAFRs (mVAFR) was computed for each patient. In our dataset, mVAFR was significantly associated with progression-free survival (PFS). Baseline VAF, on-treatment VAF or absolute changes in VAF were not associated with PFS. These findings demonstrate that ctDNA dynamics using a standardized multi-gene panel and a unique methodological approach predicts treatment outcome. Clinical trials in patients with an unfavorable ctDNA response are needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was designed by investigators from Hospital Clinic. Funding sources had no role in the design and conduction of this study, and in the analysis and interpretation of data. Guardant Health provided the assay. This study was funded by Instituto de Salud Carlos III (to A.P.), Breast Cancer Research Foundation (to A.P.), PhD4MD (to N.C.), Fundació La Marató TV3 (to A.P), RESCUER Horizon 2020 (to A.P.), Save the Mama (to A.P.), Pas a Pas (to A.P.), Asociación Cáncer de Mama Metastásico (to A.P.), Fundación Científica Asociación Española Contra el Cáncer (to F.B.M.) and Fundación SEOM (SEOM 2018 Grant: Fellowship for Training in Research in Reference Centers to T.P.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Hospital Clinic approved the study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
